Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
November/December 2010, Vol 1, No 6
November/December 2010, Vol 1, No 6
Bortezomib Bests Vincristine as Induction Therapy for MM
Cancer Quick Takes
November/December 2010, Vol 1, No 6
This study compared the safety and efficacy of a new regimen—bortezomib plus dexamethasone and vincristine— compared with vincristine (Oncovin), doxorubicin (Adriamycin), and dexamethasone (VAD) in previously untreated multiple myeloma (MM) (J Clin Oncol. 2010;28:4621-4629).
Read Article
AML Trials: Phases and Changes
Cancer Quick Takes
November/December 2010, Vol 1, No 6
A discussion of new drug development using the example of acute myeloid leukemia (AML)—but that is applicable to a broad range of diseases— outlines the problems inherent in phase 2 clinical trials that may lead to falsepositive results, and how trial design can be improved and drug development be made more efficient and less costly (Blood. 2010;116:2420-2428).
Read Article
Reversing Acute Renal Failure
Cancer Quick Takes
November/December 2010, Vol 1, No 6
In patients with multiple myeloma with light chain–induced renal failure, treatment with a combination known as BDD (bortezomib [Velcade], doxorubicin [Adriamycin], and dexamethasone [Decadron]) resulted in a high rate of myeloma and renal responses that was well tolerated by patients (J Clin Oncol. 2010;28:4635-4641).
Read Article
From Stakeholders to Community
By
Colin Gittens
Letter to our Readers
,
Value Peer-spectives
November/December 2010, Vol 1, No 6
As the last issue of this first year of publication of Value-Based Cancer Care (VBCC) reaches you, I wanted to take a moment to reflect on where VBCC has been so far and where it will be headed in 2011 and beyond.
Read Article
The Costs of Care: A Discussion We’re Not Prepared to Have—Yet
By
Denise K. Pierce
Value-Based Care
,
VBCC Perspectives
November/December 2010, Vol 1, No 6
Each year, oncologists return to their respective practices after attending the annual American Society of Clinical Oncology or American Society of Hematology meetings armed with knowledge of new drug/biologic combinations, modified regimen dosing, and other novel approaches that may provide incrementally better outcomes for cancer patients.
Read Article
Costs of Cancer Drugs Weigh on US, Canadian Minds
By
Colin Gittens
Pricing
November/December 2010, Vol 1, No 6
US and Canadian medical oncologists share similar attitudes on the costs, cost-effectiveness, and health policies concerning new cancer drugs, despite fundamental differences between the 2 countries regarding how these drugs are covered and paid for under their respective healthcare systems.
Read Article
ASCO Shares Concerns Over the Future of Cancer Research
By
Colin Gittens
Clinical Research
,
Personalized Medicine
November/December 2010, Vol 1, No 6
Concerns about the future of cancer research exist among the spectrum of researchers and regulators, and in remarks prepared for the President’s Cancer Panel: The Future of Cancer Research—Accelerating Scientific Innovation (held September 22, 2010, in Boston), American Society of Clinical Oncology (ASCO) President
George W. Sledge, Jr, MD
, outlined some of the organization’s concerns regarding new biological therapies and the future of cancer research.
Read Article
Restoring Balance to the Cancer Research Regulation Equation
By
Colin Gittens
Clinical Research
,
Personalized Medicine
November/December 2010, Vol 1, No 6
Clinical cancer research is hampered by an overly complex and cautious regulatory system, which slows the development of lifesaving drugs, increases costs, and may be unethical, according to David J. Stewart,MD, of the University of Texas M.D. Anderson Cancer Center and colleagues (Stewart DJ, et al. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol. 2010;28:2925-2935).
Read Article
Some Biologics Fail in Early-Stage Tumors
By
Caroline Helwick
Colon Cancer
,
Solid Tumors
November/December 2010, Vol 1, No 6
Some molecularly targeted agents are proving to be less effective, not more so, when administered earlier in the disease course. Researchers say this is counterintuitive, because advanced disease is associated with treatment refractoriness, and cancer agents will typically perform better in the adjuvant treatment setting than in the metastatic treatment setting.
Read Article
Cancer Drugs: NICE Rejects Costly Treatments
By
Caroline Helwick
Cancer Care
,
Personalized Medicine
November/December 2010, Vol 1, No 6
The floodgate has opened for molecularly targeted antitumor agents, and with each novel compound the cost of treating cancer soars ever higher.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma